|
The document discusses the retention of ammonium perfluorooctanoate (C-8) in the blood of TEFLON employees, estimating that approximately 40% of inhaled C-8 vapor is retained, with variations based on individual absorption rates and airborne particle sizes.
|
1982 |
AR226-1619
|
evaRnge6eL5xk5oeJMG0Bp7Zy |
3 |
|
The document discusses the decision not to pursue a program for monitoring C-8 (PFOA) blood levels in TEFLON employees due to recent findings on its embryotoxicity and declining blood levels, while supporting additional blood sampling for certain employees and emphasizing the need for a detailed epidemiological study to determine safe blood levels.
|
1982 |
AR226-1620
|
9o98xBaLgLgpyvJ6yYzYgqeq |
1 |
|
The document discusses a request to increase the frequency of blood sampling for C-8 (PFOA) data among retired male employees and those transferred from the Fluoropolymers Division to improve the understanding of C-8 elimination rates from the body.
|
1982 |
AR226-1621
|
QJ8L8ZYKZoK0qknpxm3zpg5o5 |
1 |
|
The document discusses the retention of ammonium perfluorooctanoate (C-8) in human blood among Teflon workers, suggesting modifications to the interpretation of blood concentration data to better understand human exposure and its correlation with animal models.
|
1982 |
AR226-1622
|
aJR46RLp9Lbw8vxbprw5nGbVN |
3 |
|
This document discusses the inadequacy of current data on C-8 (PFOA) blood levels and elimination rates among employees at the Teflon Polymer Division, emphasizing the need for accurate monitoring of personnel no longer exposed to C-8 to assess long-term health implications.
|
1982 |
AR226-1624
|
eg6GOzMD1mqYEw6EjbgVbDmy |
1 |
|
This document discusses the retention of ammonium perfluorooctanoate (C-8) in the blood of Teflon employees, with estimates indicating that less than 100% of inhaled C-8 vapor is retained in the body, and it takes approximately 420 days for the body to eliminate half of the accumulated C-8.
|
1982 |
AR226-1623
|
zoNpGpZ3r2M1Jjgv5k7b18Yya |
8 |
|
This document reports the analysis of 14 blood samples for perfluorooctanoate (PFOA) by gas chromatography, indicating that most samples had very low concentrations, with some indistinguishable from the blank and others below the quantitation limit.
|
1982 |
AR226-1625
|
N2gvnRvo55G2kKKKjoa9MjK5R |
2 |
|
The document reports on an acute oral toxicity study of T-3066CoC conducted on albino rats, indicating an approximate LD50 of less than 5,000 mg/kg and greater than 500 mg/kg, with behavioral reactions observed at the higher dosage.
|
1981 |
AR226-0238
|
2Je0B1jZ4O2ExjNBGq9d7dvM5 |
10 |
|
The document reports on an acute oral toxicity study of T-3065CoC conducted on albino rats, finding an LD50 greater than 5,000 mg/kg with observed symptoms including diarrhea and lethargy, and noting gastrointestinal hemorrhage in deceased animals.
|
1981 |
AR226-0246
|
aDD3MGeK1Oa7dKxJp2jBVzE9Y |
9 |
|
The document details a two-year oral toxicity and carcinogenicity study of the fluorochemical FM-3924 conducted by RIKER Laboratories, Inc. for 3M Company, focusing on its effects in rats.
|
1981 |
AR226-0257
|
pqgpeDV3Dmkv1XJJ8pDZB33d |
361 |
|
This report analyzes medical surveillance data from 1981 of Decatur chemical and film plant workers, finding no significant correlations between various health markers and total organic fluorine levels, while noting that perfluorooctanesulfonate was previously identified as a component of total organic fluorine in the sera of some employees.
|
1981 |
AR226-0035
|
8xV9eG9EMye0MQvKvZrJQY5d |
9 |
|
This document details a two-year oral toxicity and carcinogenicity study of fluorochemical FM-3924 conducted by Riker Laboratories, Inc. for 3M Company, reporting various macroscopic and microscopic observations in rats, including lesions and chronic conditions in multiple organs.
|
1981 |
AR226-0258
|
JrbD7x5ZvakopoXe7BZBQ653r |
330 |
|
The document details a two-year oral toxicity and carcinogenicity study of fluorochemical FM-3924 conducted by Riker Laboratories, Inc. for 3M Company, focusing on the effects of this compound in female rats.
|
1981 |
AR226-0261
|
GaMQ79bDGYJRzEqM372GR05Y |
275 |
|
The document details a two-year oral toxicity and carcinogenicity study of the fluorochemical FM-3924 conducted by Riker Laboratories, Inc. for 3M Company, focusing on its effects in rats.
|
1981 |
AR226-0259
|
vB9YLjed4EyjmOJ5LrB72ZRmb |
339 |
|
This document reports on a toxicity study conducted by 3M Company in 1984, evaluating the effects of perfluorooctanesulfonate (PFOS) on aquatic invertebrates (Daphnia magna), with key findings indicating various EC50 values for immobilization and reproduction, although the study's reliability is limited due to unmeasured actual concentrations and uncharacterized sample purity
|
1981 |
AR226-0110
|
19DYeM95NjrpX3dMvbrzmR4d |
14 |
|
This document details a biodegradation test (OECD 301E) conducted on a mixture containing perfluorooctanesulfonate (PFOS) and other components, indicating that the test sample was prepared with a specific concentration of PFOS and analyzed for its ready biodegradability using a mix of soil extract and wastewater effluent.
|
1981 |
AR226-0711
|
Ev1qwVewMQ7ZD0kd9jJdomv4N |
20 |
|
The document summarizes multiple biodegradation studies on a mixture containing perfluorooctanesulfonate (PFOS) from 3M's production lot number 501, indicating high Chemical Oxygen Demand (COD) and Biochemical Oxygen Demand (BOD) values, but concludes that no reliable conclusions can be drawn due to variability in results and methods used.
|
1981 |
AR226-0741
|
bBK4xjwe1rdbde68e4wNpBeXk |
18 |
|
The document details an acute toxicity test conducted on fathead minnows (Pimephales promelas) using a mixture containing perfluorooctanesulfonate (PFOS) as part of the test substance, FC-203C, which is composed of various chemicals including 1.47% PFOS, and outlines the testing methods and conditions.
|
1981 |
AR226-0742
|
MGKJaaoE44em20VKn1b5q6NXa |
14 |
|
The document details a toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) conducted by 3M on the aquatic plant species Selenastrum capricomutum, using a 96-hour exposure period to assess algal cell counts and dry weights, although the test sample's concentration of impurities may affect the accuracy of the toxicity data.
|
1981 |
AR226-0744
|
NG0kbzJML7EZm9d9YjZVDG1pQ |
10 |
|
The document reports on an acute toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) conducted on the aquatic invertebrate Daphnia magna, indicating that the results pertain to the mixture rather than the fluorochemical component alone.
|
1981 |
AR226-0745
|
5Lr1qDDYKJX9RkwkyOrmV6KMR |
3 |
|
The document details an activated sludge respiration inhibition test conducted on a mixture containing perfluorooctanesulfonate (PFOS) from a 3M production lot, indicating the test sample's composition and preparation methods, but notes that the data may not accurately reflect the toxicity of the fluorochemical component due to impurities.
|
1981 |
AR226-0746
|
g39XJ2zz6QyoQ5gNznQmnXOa |
5 |
|
The document presents fluorine measurement data for employees with PFOS exposure at a facility from 1981 to 1997, highlighting the mean fluorine levels and the number of measurements taken per employee over the years.
|
1981 |
AR226-0176
|
BRzaz0vz5gQ7x4jnpK6BJ1NJJ |
12 |
|
The document reports on an activated sludge respiration inhibition test conducted on a mixture containing 0.73% PFOS, produced by 3M, which found no acute inhibitory effect on activated sludge respiration rate at a concentration of 1,000 mg/L.
|
1981 |
AR226-0802
|
2NbmJoM36NbbzEXdMYXrRE695 |
6 |
|
The document summarizes biodegradation studies on a mixture containing perfluorooctanesulfonate (PFOS) produced by 3M, indicating that while the majority of product components are readily biodegradable, the data does not accurately reflect the biodegradation potential of the fluorochemical component.
|
1981 |
AR226-0801
|
68Y6wexj7rGdQjg0mxjb9RGg |
18 |
|
The document details an acute toxicity test conducted on fathead minnows (Pimephales promelas) using a mixture containing 0.73% perfluorooctanesulfonate (PFOS) and various other components, following a flow-through method over a 96-hour exposure period.
|
1981 |
AR226-0803
|
x51x71Drkv3xgOxYnwRDYNN7y |
14 |
|
The document details a toxicity test of a mixture containing 0.73% PFOS, conducted on the aquatic plant species Selenastrum capricomutum, using methods from USEPA and ASTM to assess algal cell counts and dry weights over a 96-hour exposure period.
|
1981 |
AR226-0805
|
wKB1wN2rnbvp79QzZeVygOYEE |
10 |
|
The document reports on a two-year oral toxicity and carcinogenicity study of fluorochemical FM-3924, conducted by Riker Laboratories, Inc. for 3M Company, focusing on its effects in rats from April 1981 to May 1983.
|
1981 |
AR226-0260
|
KM1gv4zVRjMpvMw34jm1Ny92 |
325 |
|
This document details an oral rangefinder study conducted by Riker Laboratories, sponsored by 3M, to determine the upper dose level of T-2999CoC for a subsequent teratology study in pregnant rabbits.
|
1981 |
AR226-0275
|
99407jGgKqXqLqRke08ojzMY6 |
10 |
|
The document reports on an oral teratology study of T-2999CoC, sponsored by 3M, which found that while the compound was not teratogenic in pregnant rabbits, it caused embryotoxicity at the highest dose of 15 mg/kg/day, leading to increased abortions and low neonatal survival.
|
1981 |
AR226-0276
|
X11mX9gM63dMZoxXN2knvbXg |
37 |
|
The document details the analytical results of four corn oil samples containing varying concentrations of FM-3924, indicating that while all samples were within 10% of the target concentration, the solubility of FM-3924 was low and crystallization could pose issues for a rat feeding study.
|
1981 |
AR226-0278
|
DGVndJEpRegr8bQ2GRaVb74EO |
1 |
|
The document reports on a teratology study conducted by Riker Laboratories to evaluate the effects of T-2999CoC on rat lenses during organogenesis, concluding that lens abnormalities observed were artifacts rather than compound-related effects, with no significant differences among dose groups.
|
1981 |
AR226-0282
|
GmroRww1vG9OzJ0jYRnE7mxkY |
21 |
|
This is a teratology study report (Experiment No. 0681TR0362) conducted by Riker Laboratories Inc. on the effects of T-2999CoC in two strains of rats, focusing on the histological appearance of fetal lenses following oral dosing during gestation.
|
1981 |
AR226-0283
|
B5rJXQvjpQgQeB9b0k6RRy2EL |
48 |
|
The document reports on the analytical results of four corn oil samples containing varying concentrations of FM-3924, indicating that while the samples showed good reproducibility, the solubility of FM-3924 was low and crystallization could pose issues for a rat feeding study.
|
1981 |
AR226-0285
|
0qQqNQb6gg3kJejKLObZY6G4R |
1 |
|
The memo from K. G. Lamprecht discusses the misinterpretation of a fetal rat lens artifact as a teratogenic change in Riker Experiments involving developmental eye abnormalities, clarifying that the observed changes were due to lens vesicle remnants and not actual teratogenic effects.
|
1981 |
AR226-0287
|
QXdd0g8Ym0Jx8X1y09056wZgE |
3 |
|
The document reports on a biodegradation test conducted by 3M Company on a mixture containing perfluorooctanesulfonate (PFOS), revealing high biochemical oxygen demand (BOD) values but lacking reliable conclusions due to insufficient characterization of the test substance and methodology.
|
1981 |
AR226-0898
|
4Jve4de33a9q84X88MweMEJ0Q |
9 |
|
The document reports on an acute toxicity test of a PFOS-containing mixture (FC-3041) on fathead minnows (Pimephales promelas), indicating that the test was conducted in 1981 with specific conditions and concentrations, but the toxicity data may not accurately reflect the fluorochemical component due to impurities.
|
1981 |
AR226-0901
|
44NpqBrNMj0J6wL9OevygE7va |
4 |
|
The document reports on an acute toxicity test of a mixture containing perfluorooctanesulfonate (PFOS) on the aquatic invertebrate Daphnia magna, conducted by Rand McNeilly in 1981, with specific details about the test conditions and composition of the test substance.
|
1981 |
AR226-0902
|
4abbrzrkRVoBZkD0vB8MzKdGQ |
5 |
|
The document reports on an activated sludge respiration inhibition test for a mixture containing 6% PFOS, conducted by 3M, which found no inhibition of activated sludge respiration at a concentration of 1000 mg/L.
|
1981 |
AR226-0903
|
aDLxGv0az9mGokn0yvJLnYkOy |
4 |
|
The memo from U. G. Lamprecht discusses the misinterpretation of a fetal rat lens artifact as a teratogenic effect in Riker Experiments Nos. 0680TR0008 and 0680TR0010, detailing the nature of the observed lens changes and clarifying that they were not indicative of developmental abnormalities.
|
1981 |
AR226-0329
|
da38KbZpxGy4ywj2e45Xxx9a6 |
3 |
|
The document details a toxicity study of N-ethylperfluorooctane sulfonamidoethanol (N-EtFOSE Alcohol) on freshwater green algae (Selenastrum capricomutum), indicating that the limited water solubility of the substance hindered a definitive determination of its aquatic toxicity.
|
1981 |
AR226-0361
|
LpoepznzpzrdEJXZ42NraGR77 |
14 |
|
The document is a DuPont report on the water solubility of Telomer Alcohol (C8F17CH2CH2OH), conducted under OECD guidelines, as part of the Telomer Research Program.
|
1981 |
AR226-1287
|
2NBm5pZowvveaOanMneLgYDja |
17 |
|
The document is a report by DuPont detailing the aqueous stability of 8-2 Telomer B Alcohol as a function of pH, conducted under the Telomers Research Program sponsored by The Rand Corporation.
|
1981 |
AR226-1290
|
B8eJpE0DMakLqYNkLRYJOwaYX |
31 |
|
The document discusses a study by 3-M indicating that ammonium perfluorooctanoate (C-8 compound) used in Teflon manufacture causes eye scarring in rat fetuses following maternal exposure, prompting concerns about potential risks for female employees at Parkersburg and other locations, while questioning the study's validity.
|
1981 |
AR226-1307
|
rBn1JNQpQppZ0LN26vOdjod30 |
2 |
|
Du Pont reassigned about 50 women workers at its Parkersburg, West Virginia plant after 3M reported that the chemical FC-143, linked to birth defects in rats, may pose risks to employees of childbearing age.
|
1981 |
AR226-1328
|
a1JVk5Z6vpMeY05a7anOnxbge |
1 |
|
A preliminary study indicated that the chemical FC-1-43, used at the Du Pont Company plant, may cause birth defects, leading to the transfer of about 50 women workers to new jobs while additional tests are planned.
|
1981 |
AR226-1329
|
zoD46Br531VqDmzmnnMn09p80 |
1 |
|
This letter from E.I. du Pont de Nemours & Company informs the West Virginia Division of Water Resources about toxicity information regarding ammonium perfluorooctanoate (FC-143), a surfactant used in fluoropolymer resin manufacturing, which has shown potential reproductive toxicity in preliminary animal studies conducted by 3M, prompting Du Pont to reassign female employees of childbearing capability to
|
1981 |
AR226-1330
|
JZRDpNOOday30D8kd6zaa68e |
1 |
|
The document reports that a mixture containing Perfluorooctanesulfonylamido(ethyl)acetate (PFOSAA) tested at a concentration of 1000 mg/L showed no acute inhibitory effect on activated sludge respiration, indicating that FC-127 is not expected to inhibit the activity of activated sludge, although the testing methodology lacks proper documentation and characterization.
|
1981 |
AR226-0393
|
QXp9z4b2Y5YBKq9o7vVEbR4v8 |
4 |
|
The document reports that the 96-hour LC50 for the fish species Pimephales promelas exposed to a mixture containing Perfluorooctanesulfonylamido(ethyl)acetate (PFOSAA) was determined to be 863 mg/L, based on testing conducted by 3M Company, although the toxicity results may not accurately reflect the test substance due to the presence
|
1981 |
AR226-0394
|
ppkXGxZxnkxnDb1rYYJk1Z7Dk |
5 |
|
The document is an amendment to a two-year oral toxicity and carcinogenicity study of fluorochemical FC-143 conducted by Riker Laboratories, Inc. and 3M Company, correcting a typographical error in the titles of clinical chemistry value tables without affecting the interpretation of the data.
|
1981 |
AR226-0437
|
QRQZQ9vN44qDrnZe80j9DNrL |
299 |
|
The document details a two-year oral toxicity and carcinogenicity study of fluorochemical FC-143 conducted on rats by Riker Laboratories, Inc. for 3M Company, spanning from April 1981 to May 1983.
|
1981 |
AR226-0440
|
91QXxJYZGG7L2GEZ5KrZkjkR7 |
314 |
|
The document describes an oral rangefinder study conducted by 3M Commercial Chemical Division to determine the upper dose level of T-3141CoC for a subsequent teratology study in pregnant rabbits, detailing the methodology and dosing regimen used.
|
1981 |
AR226-0464
|
6BEvrBVbLaXGqLyRRK5ne3zbR |
8 |
|
The document reports on an oral teratology study of T-2998CoC conducted by Riker Laboratories, sponsored by 3M, which found that the compound was not teratogenic in pregnant rats, although it caused maternal toxicity at the highest dose of 150 mg/kg/day.
|
1981 |
AR226-0463
|
mqjL6kr3VKwE2x6pxekqDykB0 |
40 |
|
The internal correspondence discusses the results of health evaluations conducted in 1981 at the Chemolite plant, highlighting significant abnormalities among employees, including elevated blood pressure and cholesterol levels, which may indicate potential health risks related to exposure to perfluorinated compounds.
|
1981 |
AR226-0481
|
XREL516bj2qxz8bypE4982NR4 |
3 |
|
The document reports the calculation of the octanol/water partition coefficient for perfluorooctanoic acid, ammonium salt (FC-143), conducted by 3M Company, indicating a logP0w of approximately -0.9, suggesting a low tendency for the compound to partition into octanol.
|
1981 |
AR226-0493
|
dmqj5ODDnK419gV2DX1XDqkQ |
2 |
|
This document details a 1981 acute static toxicity study of perfluorooctanoic acid ammonium salt (PFOA ammonium salt) on the aquatic plant species Selenastrum capricornutum, conducted by the USEPA, which involved various test concentrations and analytical monitoring of algal cell counts and weights.
|
1981 |
AR226-0506
|
OBjMwO09x1qd4rQqg0OJndNw |
20 |
|
The document contains questions and concerns from the public directed at DuPont regarding the safety and health risks associated with C-8 (PFOA) in drinking water, including inquiries about the company's intentions to stop its use, the long-term health effects, and the impact on property values.
|
1981 |
AR226-1689
|
VVZ4M8QGx6wb87rxggxygqkp |
2 |
|
The document describes a study conducted by researchers from 3M Company that utilized a gas chromatographic technique to analyze the biotransformation of 1H,1H,2H,2H-perfluorodecanol in adult male rats, identifying perfluorooctanoate as a metabolite and suggesting a defluorination process during metabolism.
|
1981 |
AR226-1440
|
8KVZdYoJDOR401nkYv890Kwy |
8 |
|
The memo from E. I. du Pont de Nemours & Company discusses the potential risks of FC-143 (Ammonium perfluorooctanoate) based on a 3M pilot study that showed it caused abnormal eye lenses in rat fetuses, recommending the removal of women of childbearing capacity from exposure to FC-143 if blood levels exceed 0.4 ppm.
|
1981 |
AR226-1494
|
mmz20domqb1nED2BVMzYY0pkb |
3 |
|
This document is an analytical report from DuPont detailing the analysis of 27 blood samples for perfluorooctanoate (PFOA) using gas chromatography, including a comparison of results from different analytical methods.
|
1981 |
AR226-1561
|
2OpVqEYqgqXK5oBoqbYd8Nr |
2 |
|
The document outlines plans for communication and employee reassignment regarding potential exposure to ammonium perfluorooctanoate (C-8) at various production sites, noting blood levels of C-8 in employees and comparing them to background levels, while indicating that some employees will be removed from exposure and others will undergo additional testing.
|
1981 |
AR226-1562
|
dQ9brVzYqqmLvr8B6K3KbpGaq |
2 |
|
The document outlines a blood sampling program for employees exposed to C-8 (perfluorooctanoic acid, PFOA) to analyze organic fluorine levels and assess the elimination rate of C-8 from the body, specifically targeting female employees who have worked with TEFLON.
|
1981 |
AR226-1563
|
oK7RKYxbDkLnzEXmQjXxnOE |
1 |
|
The document discusses the lack of direct correlation between airborne C-8 (PFOA) concentrations and organic fluorine levels in blood samples, indicating that C-8 accumulates in the blood over time, with specific blood levels observed in monomer operators reflecting prolonged exposure rather than immediate elimination.
|
1981 |
AR226-1564
|
e7QJ6J5MXxDZ6Oe2V0XVbVVoq |
2 |
|
This memo from DuPont discusses a change in the analytical test method for measuring perfluorooctanoic acid (C-8) in blood samples of personnel, indicating that the new gas chromatography method yields results approximately 282% higher than the previous bomb analysis method.
|
1981 |
AR226-1565
|
YrGZr8B5w48Rw9YgODYg2b59y |
1 |
|
The document discusses DuPont's ongoing program related to Ammonium Perfluorooctanoate (FC-143), highlighting concerns about potential health effects on female employees, including blood analysis for exposure, a planned inhalation teratology study in rats, and the consideration of further epidemiological studies.
|
1981 |
AR226-1566
|
mbqyEKyNgMV9X78rQGoMM28D4 |
6 |
|
The document discusses ongoing blood level testing for C-8 (perfluorooctanoic acid, PFOA) among exposed employees and controls, noting that controls have shown non-detectable levels, while an animal study has been initiated to determine a "no-effect" level in rats.
|
1981 |
AR226-1568
|
GKVrJBMp24L4LG2BexpxkoBDx |
1 |
|
The memo discusses the potential risks of FC-143 (Ammonium perfluorooctanoate) based on a pilot study by 3M that linked it to abnormal eye lenses in rat fetuses, recommending the removal of women of childbearing capacity from exposure to FC-143 if blood levels exceed 0.4 ppm, while noting that recent measurements indicate background levels in Wilmington office workers
|
1981 |
AR226-1569
|
5bOJdR7g8b9oNQv4Rprn8DJND |
3 |
|
This document reports the analysis of 48 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the method used, precision, and quantitation limits of the results.
|
1981 |
AR226-1570
|
nmQDyJXGqMbJvK8wQa0mGQGX8 |
4 |
|
The document reports the analysis of 48 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, analytical methods, and precision of the measurements.
|
1981 |
AR226-1571
|
4vpdE0RVDZKma323Xonrx9VEN |
3 |
|
The document reports the analysis of nine blood samples for perfluorooctanoate (PFOA) conducted by DuPont's Haskell Laboratory, detailing the results, methodology, and precision of the gas chromatographic method used.
|
1981 |
AR226-1573
|
DMQqpXr8J7wxbVO0vj9D66MZM |
2 |
|
The document reports the analysis of 27 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, analytical methods, and precision of the measurements.
|
1981 |
AR226-1574
|
6xzJJL0Z3NxYg9Z4kpMkLKo1 |
3 |
|
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, methodology, and precision of the gas chromatographic method used for quantification.
|
1981 |
AR226-1575
|
pBr4yRaKy81j5yYBN97ap2ZZB |
2 |
|
This document reports the analysis of 14 blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, detailing the methodology, precision, and quantitation limits of the results.
|
1981 |
AR226-1576
|
QMEyNZ3wamGKmdX3opBmkdOkE |
2 |
|
The document details the analysis of 18 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, reporting results with a lower limit of quantitation of 0.01 ppm PFOA and a detection limit of approximately 0.004 ppm.
|
1981 |
AR226-1577
|
6B7B0YRYGByEJR9Zmy77np4Y3 |
2 |
|
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results and methodology used, including a gas chromatographic method with specific quantitation limits.
|
1981 |
AR226-1578
|
z42Dk71ygyNQdoj3OVaLv4Ga |
4 |
|
This document reports the analysis of 16 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the method used, precision of results, and providing concentration data for each sample.
|
1981 |
AR226-1579
|
emjkz9O2ykJkJQ2jvqXVZonEE |
2 |
|
This document reports the analysis of five blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours & Company, detailing the results and methodology used, including a gas chromatographic method with specific detection limits.
|
1981 |
AR226-1581
|
ZnXezBrmRMBjpDERezmRZmeZd |
2 |
|
This document reports the analysis of five blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, indicating varying concentrations with a detection limit of approximately 0.004 ppm.
|
1981 |
AR226-1580
|
4v1Mr53kQp0OvagBB2BGKLO1V |
2 |
|
The document outlines a revised voluntary program for monitoring blood levels of organic fluorine (measured as C-8, which refers to PFOA) among employees involved in the production of TEFLON Polymers and Copolymers during 1981 and 1982.
|
1981 |
AR226-1582
|
152xqq4Y59M6mOakpLELL1b5K |
3 |
|
This document reports the analysis of six blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the concentrations found and the methods used for quantification.
|
1981 |
AR226-1584
|
6ybyz98EYE0wQGEmq1be9JKE |
2 |
|
The document details the analysis of 11 blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, reporting results with a lower limit of quantitation of 0.01 ppm PFOA and a detection limit of approximately 0.004 ppm.
|
1981 |
AR226-1583
|
kDmQY4OjnDd03bOdG3qZXYY0J |
2 |
|
The document reports the analysis of 21 blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours & Company, detailing the results and methodology used, with a detection limit of 0.004 ppm.
|
1981 |
AR226-1585
|
V3yo5GaRNZ4XQM63YjEeY9aGo |
2 |
|
This document reports the analysis of 36 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results and methodology used, including a gas chromatographic method with specific detection limits.
|
1981 |
AR226-1586
|
qm0JwExpKRMEGXbqBy3jMX9Qn |
3 |
|
This document reports the analysis of 35 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the results, methodology, and precision of the measurements.
|
1981 |
AR226-1587
|
NE8J2nNqzpNe5YmnM8pVedqRR |
3 |
|
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, indicating that the samples tested showed no detectable levels of PFOA.
|
1981 |
AR226-1588
|
B8KyDR0RGydM8EEz4rQ73L794 |
2 |
|
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont, revealing specific concentration levels of PFOA in the samples using a gas chromatographic method.
|
1981 |
AR226-1590
|
dQzb5qBZjReoVypEG4d0yk6YR |
2 |
|
This document reports the analysis of 21 blood samples for perfluorooctanoate (PFOA) conducted by DuPont, detailing the method used, precision of results, and concentration levels found in the samples.
|
1981 |
AR226-1589
|
NeY3y0nVrq0yDJ9VmpEM2jokV |
4 |
|
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours & Company, detailing the results and methodology used, including a gas chromatographic method with a detection limit of 0.004 ppm.
|
1981 |
AR226-1591
|
qd4Qx1d20NJ64RL6DKLQv7gX5 |
2 |
|
The document reports the analysis of a blood sample for perfluorooctanoate (PFOA) conducted by DuPont, revealing a concentration of 0.17 ppm F, with details on the analytical method and precision.
|
1981 |
AR226-1592
|
mBnjeGNzZLqRazo6B4K8RNzOg |
1 |
|
The document outlines the expansion of a voluntary blood sampling program for C-8 (PFOA) among employees in the Fluoropolymers Division, mentions ongoing embryotoxic testing at Haskell Laboratories, and describes an increased air monitoring program to assess exposure levels.
|
1981 |
AR226-1593
|
ZJnpK87dMX5dMRn70L27bbok0 |
8 |
|
The document outlines plans for additional blood sampling of individuals exposed to C-8 (PFOA) in a TEFLON production context, scheduled to be completed within four weeks.
|
1981 |
AR226-1594
|
Z4GGk31kLbex14YkxXweORvGO |
2 |
|
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, detailing the results and methodology used, with concentrations found ranging from 0.043 to 0.33 ppm.
|
1981 |
AR226-1595
|
e7aEjj3B5pD55K08dNvdbxk0m |
2 |
|
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont de Nemours Company, detailing the concentrations found in various samples collected in July 1981.
|
1981 |
AR226-1596
|
O3pnE376E2BL0RKoBw3ZY7K6p |
3 |
|
The document presents analytical results of FC-143 (Ammonium Perfluorooctanoate) levels in blood samples from individuals associated with polymer products at Chambers Works, showing a range of concentrations from 0 to 0.250, with an overall mean of 0.049.
|
1981 |
AR226-1597
|
Dz258bMxqXn2OYzDrRdgJyBB |
1 |
|
The document outlines the results of a biological monitoring program for FC-143 (ammonium perfluorooctanoate) in blood samples from employees, detailing the communication plan for notifying personnel about the findings and individual results.
|
1981 |
AR226-1598
|
n90m378X0on78Oyd4524Qk7Ew |
6 |
|
This document reports the analysis of 41 blood samples for perfluorooctanoate (PFOA) conducted by E. I. du Pont de Nemours and Company, detailing the results and sample identification from the gas chromatographic method used.
|
1981 |
AR226-1599
|
4aq0q345nn1Ed2zq000o9mq0Q |
3 |
|
This document reports the analysis of 53 blood samples for perfluorooctanoate (PFOA) conducted by DuPont de Nemours & Company, detailing the concentrations found in each sample.
|
1981 |
AR226-1602
|
vV3GJYbxn4pqRNoK1XXnnE5RY |
3 |
|
This document reports the analysis of 37 blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours & Company, detailing the concentrations found in each sample.
|
1981 |
AR226-1603
|
oeRZMgYMG40YY5Jrv65ZO9k4r |
3 |
|
The document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by DuPont de Nemours, revealing various concentrations of PFOA in the samples analyzed between September 22 and October 5, 1981.
|
1981 |
AR226-1605
|
oeDRoEZV32dRw3KbnL8oQyygg |
3 |
|
This document reports the analysis of blood samples for perfluorooctanoate (PFOA) conducted by E.I. du Pont de Nemours and Company, detailing the concentrations found in various samples collected in October 1981.
|
1981 |
AR226-1606
|
gQ2Jaz6gLbaMwRno9pvK4KGa |
3 |
|
The document reports on a study of C-8 (PFOA) blood levels in eighteen females transferred out of the Teflon divisions at DuPont's Washington Works, indicating a statistically significant average decrease of 15% in blood C-8 levels over approximately 129 days.
|
1981 |
AR226-1607
|
J3y7MVJg7x3az8vZjpd0VQqYa |
24 |